Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2 in Obese
Interventions:   Drug: Cyclo-Z;   Drug: Placebo
Sponsor:   NovMetaPharma Co., Ltd.
Not yet recruiting - verified May 2016

Effect of Liraglutide on Clock Genes

Condition:   Type 2 Diabetes
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsor:   Tel Aviv University
Not yet recruiting - verified May 2016

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified May 2016

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2016

Meta-analyses of the Effect of 'Catalytic' Doses of Fructose and Its Epimers on Carbohydrate Metabolism

Conditions:   Overweight;   Obesity;   Dysglycemia;   Prediabetes;   Metabolic Syndrome;   Type 2 Diabetes
Intervention:   Other: fructose, allulose, tagatose, or sorbose
Sponsors:   University of Toronto;   Canadian Diabetes Association;   The Physicians' Services Incorporated Foundation;   Banting and Best Diabetes Centre;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified May 2016

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Condition:   Diabetes Mellitus
Interventions:   Dietary Supplement: Vitamin E;   Other: Placebo
Sponsors:   Tan Tock Seng Hospital;   Lee Kong Chian School of Medicine, Nanyang Technological University;   National Medical Research Council (NMRC), Singapore
Recruiting - verified May 2016

Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes;   Cold Acclimation
Intervention:   Other: Chronic cold acclimation
Sponsor:   Xiang Guang-da
Recruiting - verified May 2016

Meta-analyses of the Effect of Liquid Meal Replacements on Cardiometabolic Risk

Conditions:   Overweight;   Obesity;   Type 2 Diabetes
Intervention:   Other: Liquid Meal Replacements
Sponsors:   John Sievenpiper;   Canadian Institutes of Health Research (CIHR);   The Physicians' Services Incorporated Foundation;   Canadian Diabetes Association;   Banting and Best Diabetes Centre
Active, not recruiting - verified May 2016

Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome

Condition:   Metabolic Syndrome
Interventions:   Drug: Metformin;   Dietary Supplement: Agave inulin;   Other: Placebo of agave inulin;   Other: Metformin placebo
Sponsor:   Centro Universitario de Ciencias de la Salud, Mexico
Completed - verified May 2016

Lipolytic Effects of GH in Human Subjects in Vivo

Conditions:   Metabolic Diseases;   Growth Hormone Treatment
Interventions:   Drug: Growth Hormone;   Drug: Pegisomant
Sponsor:   University of Aarhus
Recruiting - verified May 2016

Lipolytic Effects of GH in Hypopituitary Patients in Vivo

Conditions:   Hypopituitarism;   Insulin Resistance;   Endocrine System Diseases;   Glucose Metabolism Disorders;   Metabolic Diseases;   Pituitary Diseases;   Brain Diseases
Interventions:   Drug: Acipimox;   Drug: Placebo;   Drug: GH substitution;   Other: GH pause
Sponsor:   University of Aarhus
Recruiting - verified May 2016

Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters (PSV, EDV, RI) of Retrobulbar Blood Vessels (CRA, PCA, and OA) in 48 T2DM Patients Did Not Combinate With DR

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: spirometer;Intraocular pressure;Color doppler imaging
Sponsor:   Fourth People's Hospital of Shenyang
Completed - verified May 2016

Impact of Ageing on Adipose, Muscle and Systemic Inflammation

Conditions:   Inflammation;   Aging
Intervention:   Other: Maintaining a normal daily living lifestyle
Sponsor:   University of Bath
Recruiting - verified May 2016

A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Conditions:   Healthy;   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LY3298176;   Drug: Placebo;   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Recruiting - verified May 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified May 2016

Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients

Condition:   Diabetes
Interventions:   Other: ACP Living with Diabetes Guide;   Other: ADA Living Well with Diabetes Workbook
Sponsors:   University of Arkansas;   Northwestern University;   Louisiana State University Health Sciences Center Shreveport;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified May 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified May 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified May 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2016

Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)

Condition:   Diabetic Neuropathic Pain
Intervention:   Genetic: Identification of genetic causes of diabetic neuropathic pain
Sponsors:   University of Dundee;   Wellcome Trust;   Diabetes UK
Recruiting - verified May 2016

Goji Berries and Energy Expenditure

Condition:   Overweight
Interventions:   Dietary Supplement: Lycium Barbarum mixed meal;   Dietary Supplement: Control mixed meal
Sponsor:   Maastricht University Medical Center
Recruiting - verified April 2016

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Metformin
Sponsor:   AstraZeneca
Withdrawn - verified May 2016

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified May 2016

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Recruiting - verified May 2016

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Condition:   Inappropriate ADH Syndrome
Interventions:   Other: Induced hypotonic hyponatremia - SIAD model;   Drug: Empagliflozin 25mg Tbl;   Drug: Placebo P-Tablet
Sponsor:   University Hospital, Basel, Switzerland
Recruiting - verified May 2016

Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases

Conditions:   Diabetes Mellitus, Type 2;   Metabolic Syndrome X;   Hypertension;   Cardiovascular Diseases;   Stroke
Intervention:   Other: Fructose-containing Sugars
Sponsors:   University of Toronto;   Canadian Institutes of Health Research (CIHR);   The Physicians' Services Incorporated Foundation;   Canadian Diabetes Association (CDA)
Active, not recruiting - verified May 2016

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LGD-6972 Solution;   Drug: LGD-6972 Capsules
Sponsors:   Ligand Pharmaceuticals;   Medpace, Inc.
Completed - verified March 2016

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Condition:   Type 2 Diabetes Mellitus (T2DM)
Intervention:   Behavioral: Lifestyle intervention
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified May 2016

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Condition:   Dyslipidemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: statins;   Drug: ezetimibe;   Drug: fenofibrate;   Drug: nicotinic acid;   Drug: omega-3 fatty acids
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2016

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified May 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified May 2016

Use of Santyl in Diabetic Foot Ulcers

Conditions:   Diabetic Foot;   Foot Ulcer, Diabetic
Interventions:   Biological: Santyl;   Other: Product containing silver
Sponsor:   Smith & Nephew, Inc.
Recruiting - verified May 2016

Novel Stromal Cell Therapy for Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Biological: Mesenchymal Stromal Cells;   Other: Placebo
Sponsors:   Mario Negri Institute for Pharmacological Research;   Leiden University Medical Center;   NHS Blood and Transplant;   A.O. Ospedale Papa Giovanni XXIII;   Istituto Di Ricerche Farmacologiche Mario Negri;   Belfast Health and Social Care Trust;   National University of Ireland, Galway, Ireland;   University Hospital Birmingham
Not yet recruiting - verified May 2016

A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes

Conditions:   Collaborative Implementation Intentions;   Individual Implementation Intentions;   Information Only Control Condition
Interventions:   Behavioral: Collaborative implementation Intentions;   Behavioral: Individual implementation Intentions;   Behavioral: Control
Sponsor:   University of Colorado, Denver
Recruiting - verified May 2016

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified May 2016

Bexagliflozin Efficacy and Safety Trial (BEST)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Recruiting - verified May 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2016

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified May 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2016

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Type 2
Interventions:   Drug: ORMD-0801;   Drug: Placebo Comparator
Sponsors:   Oramed, Ltd.;   Integrium
Completed - verified May 2016

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Weill Medical College of Cornell University;   Brigham and Women's Hospital
Recruiting - verified May 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2016

Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy

Condition:   Type 2 Diabetes
Interventions:   Other: 24-hour intervention with multiple daily injections;   Other: 24-hour intervention with closed-loop strategy;   Drug: Insulin;   Device: Insulin pump MiniMed® Paradigm® Veo™;   Device: Continuous Glucose Monitoring System Enlite sensor®
Sponsors:   Institut de Recherches Cliniques de Montreal;   Réseau de recherche en santé cardiométabolique, diabète et obésité
Recruiting - verified May 2016

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified May 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
Recruiting - verified May 2016

The Fructose and Allulose Catalytic Effects (FACE) Trial

Condition:   Type 2 Diabetes
Interventions:   Other: Allulose;   Other: Fructose;   Other: Control
Sponsors:   University of Toronto;   Tate & Lyle
Recruiting - verified May 2016

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Glargine;   Drug: Oral antidiabetic drugs;   Drug: Rapid-acting insulin analogs
Sponsor:   Emory University
Recruiting - verified May 2016

Community-based Adolescent Diabetes Prevention Program

Condition:   Pre-Diabetes
Intervention:   Behavioral: TEEN HEED
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2016

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

Conditions:   Tissue and Organ Harvesting;   Liver Transplantation;   Brain Death
Intervention:   Procedure: Fibroscan
Sponsor:   University Hospital, Limoges
Recruiting - verified May 2016

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified May 2016

Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)

Conditions:   Diabetes;   Executive Dysfunction
Interventions:   Drug: Cholecalciferol;   Drug: Cholecalciferol
Sponsors:   Loyola University;   University of Chicago
Recruiting - verified May 2016

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Regular Human Insulin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Novo Nordisk A/S;   Medtronic;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2016

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Bexagliflozin tablets
Sponsor:   Theracos
Active, not recruiting - verified May 2016

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

Conditions:   Cirrhosis;   Diabetes Mellitus, Type 2
Intervention:   Device: Continuous glucose monitor (Dexcom, San Diego, CA)
Sponsor:   University of Arkansas
Active, not recruiting - verified May 2016

Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer

Condition:   Diabetic Foot
Interventions:   Behavioral: SMS and voice messaging;   Device: Thermometry
Sponsors:   Universidad Peruana Cayetano Heredia;   Johns Hopkins University;   Mayo Clinic;   Southern Arizona Limb Salvage Alliance (SALSA)
Active, not recruiting - verified May 2016

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: GEMIGLIPTIN LS15-0444;   Drug: vildagliptin;   Drug: metformin
Sponsor:   Sanofi
Completed - verified May 2016

Mechanisms of Endothelial Dysfunction in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Biological: Blood samples
Sponsor:   University Hospital, Rouen
Recruiting - verified May 2016

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2016

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5 mg;   Drug: Placebo 5 mg for Saxagliptin;   Drug: Placebo 500 mg for metformin (with titration);   Drug: Metformin 500 mg with titration
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2016

Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Other: ADR-1;   Other: GMNL-263;   Other: placebo
Sponsor:   GenMont Biotech Incorporation
Recruiting - verified May 2016

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Recruiting - verified May 2016

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Completed - verified May 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

The Differential Effects of Diabetes Therapy on Inflammation

Conditions:   Diabetic Nephropathy;   Type 2 Diabetes
Interventions:   Drug: Dipeptidyl-Peptidase IV Inhibitors;   Drug: Glucagon-Like Peptide 1
Sponsors:   University College Dublin;   Irish Endocrine Society;   Royal College of Physicians;   Merck Sharp & Dohme Corp.;   Eli Lilly and Company
Completed - verified May 2016

The WISE (Weightloss Intervention Surgical Effects) Brain Study

Conditions:   Diabetes;   Weightloss
Interventions:   Procedure: Bariatric Surgery Candidates;   Other: Non surgical/Community volunteers
Sponsors:   University of Florida;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2016

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Linagliptin 5 mg QD (N=24);   Drug: Glimepiride 1 mg QD (N=24)
Sponsor:   VU University Medical Center
Completed - verified May 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Biological: BMS-986036;   Biological: Placebo (Matching with BMS-986036)
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

Conditions:   Chronic Low Back Pain;   Type 2 Diabetes Mellitus
Interventions:   Other: Osteopathic Manual Treatment (OMT);   Other: Sham OMT
Sponsors:   University of North Texas Health Science Center;   American Osteopathic Association;   Osteopathic Heritage Foundations
Terminated - verified May 2016

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified May 2016

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified May 2016

Improving Diabetes Outcomes for Persons With Severe Mental Illness

Condition:   Diabetes
Intervention:   Behavioral: Diabetes self-management and education
Sponsors:   University of North Carolina, Chapel Hill;   North Carolina Translational and Clinical Sciences Institute
Recruiting - verified May 2016

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified May 2016

Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Linagliptin;   Drug: placebo
Sponsors:   dr. DJ Mulder;   Boehringer Ingelheim
Completed - verified May 2016

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified May 2016

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified March 2016

Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus

Conditions:   Diabetic Neuropathy;   Cognitive Impairment
Interventions:   Dietary Supplement: Tocotrienol;   Dietary Supplement: Placebo
Sponsors:   University of Science Malaysia;   Clinical Research Centre, Malaysia;   Malaysia Palm Oil Board
Active, not recruiting - verified May 2016

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified May 2016

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Interventions:   Drug: Regular Insulin;   Drug: Humalog
Sponsor:   Emory University
Recruiting - verified May 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2016

Oklahoma Native American Women's Osteoporosis Screening Study

Condition:   Osteoporosis
Intervention:  
Sponsor:   Oklahoma State University
Active, not recruiting - verified May 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

Sunshine 2 Study for Women With Diabetes

Conditions:   Diabetes;   Depression;   Quality of Life
Interventions:   Drug: Vitamin D3;   Drug: Vitamin D3 comparator
Sponsors:   Loyola University;   National Institutes of Health (NIH);   National Institute of Nursing Research (NINR)
Recruiting - verified May 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women

Condition:   Diabetes
Intervention:   Behavioral: Lifestyle Intervention
Sponsor:   University of Massachusetts, Amherst
Recruiting - verified May 2016

GLP-1 and Hypoglycemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
Sponsor:   University of Maryland
Recruiting - verified May 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2016

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Condition:   Type 2 Diabetes
Intervention:   Drug: ITCA 650 (exenatide in DUROS)
Sponsor:   Intarcia Therapeutics
Active, not recruiting - verified May 2016

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2016

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified May 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

Study of a Postpartum Diabetes Prevention Program for Hispanic Women

Condition:   Diabetes
Intervention:   Behavioral: Lifestyle Intervention
Sponsors:   University of Massachusetts, Amherst;   University of California, San Diego;   Northeastern University;   Baystate Medical Center;   University of Massachusetts, Worcester
Recruiting - verified May 2016

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

Conditions:   Heart Failure;   Obesity;   Type 2 Diabetes Mellitus;   Health Normal Volunteer Subjects
Intervention:   Drug: [18F]FluorbetaOx
Sponsor:   Washington University School of Medicine
Active, not recruiting - verified May 2016

Cardiovascular Inflammation Reduction Trial

Condition:   Cardiovascular Disease
Interventions:   Drug: Methotrexate;   Drug: Placebo
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2016

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   AstraZeneca
Recruiting - verified May 2016

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified May 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2016

Effects of a High Protein Diet on Clinical Outcomes in Heart Failure

Conditions:   Heart Failure;   Diabetes Mellitus
Intervention:   Procedure: 12-week supervised weight loss intervention
Sponsors:   University of California, Irvine;   University of California, Los Angeles
Completed - verified May 2016

The Effect of Gastric Bypass Surgery on Diabetes

Condition:   Type II Diabetes
Intervention:  
Sponsors:   University of Oulu;   Oulu University Hospital
Recruiting - verified May 2016

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

Conditions:   Diabetes;   Diabetic Retinopathy
Intervention:   Behavioral: Diabetes Education
Sponsors:   Diabetic Retinopathy Clinical Research Network;   National Eye Institute (NEI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 2016

Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus

Condition:   Macular Edema Following Cataract Surgery
Interventions:   Drug: Trientine Hydrochloride;   Other: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
Sponsor:   University of British Columbia
Not yet recruiting - verified May 2016

Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

Conditions:   Diabetes Mellitus, Type 2;   Adult
Interventions:   Drug: Ertugliflozin 2 mg single dose;   Drug: Ertugliflozin 2 mg split into twice daily;   Drug: Ertugliflozin 4 mg single dose;   Drug: Ertugliflozin 4 mg split into twice daily;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified May 2016

Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: FDSME group;   Behavioral: FDSME
Sponsor:   Tehran University of Medical Sciences
Completed - verified May 2016

A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)

Condition:   Healthy Volunteer
Interventions:   Drug: Ertugliflozin;   Drug: Placebo to Ertugliflozin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified May 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified May 2016

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Conditions:   Birth Defects;   Type 2 Diabetes;   Preterm Birth
Intervention:  
Sponsor:   AstraZeneca
Terminated - verified May 2016

Medication in Early Diabetes (MED) Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Pioglitazone;   Drug: Metformin
Sponsor:   Menzies School of Health Research
Withdrawn - verified April 2009

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions:   Diabetic Nephropathy;   Diabetes Mellitus;   Diabetic Kidney Disease;   Albuminuria
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2016